Search results
Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while ...
Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while ...
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.
Jan 31, 2024 · Biogen will focus on LEQEMBI® (lecanemab-irmb) with Eisai and advancing potential new modalities to address the multiple pathologies of the disease and unmet patient needs. A plan for patients participating in clinical trials or on commercially available treatment is in place.
Jul 28, 2023 · Proposed acquisition represents meaningful step forward in Biogen’s strategy for sustainable growth, adding a highly complementary innovative product in an area of high unmet medical need; Expected to be significantly accretive to Biogen’s Non-GAAP diluted EPS beginning in 2025; Biogen to host investor conference call today at 9:00 a.m. ET.
1 day ago · Drug or Therapy. Stage of development & indication. Mechanism. Eli Lilly and Co (LLY.N) Kisunla. Secured U.S. FDA's standard approval for early Alzheimer’s. Designed to target and remove toxic ...
1 day ago · Biogen is known for its neuroscience focus, having co-developed the next-generation Alzheimer’s treatment Leqembi (lecanemab-irmb) with Eisai. The drug is predicted to see US sales of $4.6bn by ...
